文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

高危子宫内膜癌辅助放化疗与单纯放疗后长期毒性与健康相关生活质量的随机试验分析

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-10-28

PORTEC-3试验中660例高危子宫内膜癌患者随机接受放化疗或单纯盆腔放疗,中位随访74.6个月。

要点

  • 两组长期总体健康/生活质量相似且优于常模人群,躯体与角色功能差异至3年。

核心结论

  • 放化疗对毒性和健康相关生活质量有长期、临床相关的负面影响,最突出的是持续性外周感觉神经病变。
  • 躯体功能和角色功能损害持续至3年,但两组长期总体健康/生活质量相似且优于常模人群。

研究设计与样本

  • PORTEC-3随机试验的长期毒性及健康相关生活质量分析,660例高危子宫内膜癌患者随机接受放化疗(2周期顺铂同步后4周期卡铂/紫杉醇)或单纯放疗。
  • 毒性采用CTCAE 3.0分级,HRQOL采用EORTC QLQ-C30及CX24/OV28子量表并与常模数据比较,行按治疗分析。
  • 中位随访74.6个月,574例(87%)患者可评估HRQOL。

主要发现

  • 两组长期总体健康/生活质量评分相似,且均优于常模人群。

临床怎么用

  • 这些长期数据可用于高危子宫内膜癌辅助化疗的患者信息告知和共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic radiation therapy alone. The present analysis was performed to compare long-term adverse events (AE) and health-related quality of life (HRQOL). METHODS AND MATERIALS: In the study, 660 women with high-risk endometrial cancer were randomly assigned to receive chemoradiation therapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel) or radiation therapy alone. Toxicity was graded using Common Terminology Criteria for Adverse Events, version 3.0. HRQOL was measured using EORTC QLQ-C30 and CX24/OV28 subscales and compared with normative data. An as-treated analysis was performed. RESULTS: Median follow-up was 74.6 months; 574 (87%) patients were evaluable for HRQOL. At 5 years, grade ≥2 AE were scored for 78 (38%) patients who had received chemoradiation therapy versus 46 (24%) who had received radiation therapy alone (P = .008). Grade 3 AE did not differ significantly between the groups (8% vs 5%, P = .18) at 5 years, and only one new late grade 4 toxicity had been reported. At 3 and 5 years, sensory neuropathy toxicity grade ≥2 persisted after chemoradiation therapy in 6% (vs 0% after radiation therapy, P < .001) and more patients reported significant tingling or numbness at HRQOL (27% vs 8%, P < .001 at 3 years; 24% vs 9%, P = .002 at 5 years). Up to 3 years, more patients who had chemoradiation therapy reported limb weakness (21% vs 5%, P < .001) and lower physical (79 vs 87, P < .001) and role functioning (78 vs 88, P < .001) scores. Both treatment groups reported similar long-term global health/quality of life scores, which were better than those of the normative population. CONCLUSIONS: This study shows a long-lasting, clinically relevant, negative impact of chemoradiation therapy on toxicity and HRQOL, most importantly persistent peripheral sensory neuropathy. Physical and role functioning impairments were seen until 3 years. These long-term data are essential for patient information and shared decision-making regarding adjuvant chemotherapy for high-risk endometrial cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Post CCB, de Boer SM, Powell ME, et al. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 33129910. doi:10.1016/j.ijrobp.2020.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。